SYMPHONY consortium
The SYMPHONY consortium which aims to orchestrate personalised treatment
in patients with bleeding disorders, is a unique collaboration between
patients, health care professionals and translational & fundamental
researchers specialised in inherited bleeding disorders, as well as
experts from multiple disciplines. It aims to identify best treatment
choice for each individual based on bleeding phenotype. In order to
achieve this goal, workpackages have been organized according to three
themes e.g. Diagnostics (workpackages 3&4); Treatment (workpackages
5-9) and Fundamental Research (workpackages 10-12). This research
receives funding from the Netherlands Organisation for Scientific
Research (NWO) in the framework of the NWA-ORC Call grant agreement
NWA.1160.18.038. Principal investigator: Dr. M.H. Cnossen. Project
coordinator: Dr. S.H. Reitsma.
Beneficiaries of the SYMPHONY consortium: Erasmus University Medical
Center-Sophia Children’s Hospital, project leadership and coordination;
Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical
Centers; University Medical Center Groningen; University Medical Center
Utrecht; Leiden University Medical Center; Radboud University Medical
Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands
Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring
B.V., Swedish Orphan Biovitrum (Belgium) BVBA/SPRL. Additional
beneficiaries, not included in the SYMPHONY consortium, currently
funding parallel projects are: Novonordisk (OPTI-CLOT TARGET), Roche
(Partitura), Stichting Haemophilia (patient-reported outcomes project).